Cargando…
Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review
Failure in cancer drug development exacts heavy burdens on patients and research systems. To investigate inefficiencies and burdens in targeted drug development in cancer, we conducted a systematic review of all prelicensure trials for the anticancer drug, sorafenib (Bayer/Onyx Pharmaceuticals). We...
Autores principales: | Mattina, James, Carlisle, Benjamin, Hachem, Yasmina, Fergusson, Dean, Kimmelman, Jonathan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291369/ https://www.ncbi.nlm.nih.gov/pubmed/28158308 http://dx.doi.org/10.1371/journal.pbio.2000487 |
Ejemplares similares
-
Patient burden and clinical advances associated with postapproval monotherapy cancer drug trials: a retrospective cohort study
por: Carlisle, Benjamin Gregory, et al.
Publicado: (2020) -
Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration
por: Hutchinson, Nora, et al.
Publicado: (2021) -
Contest models highlight inherent inefficiencies of scientific funding competitions
por: Gross, Kevin, et al.
Publicado: (2019) -
Can cancer researchers accurately judge whether preclinical reports will reproduce?
por: Benjamin, Daniel, et al.
Publicado: (2017) -
Sorafenib in the treatment of patients with hepatocellular carcinoma (HCC) and microvascular infiltration: a systematic review and meta-analysis
por: Gu, Wang, et al.
Publicado: (2020)